

Nigel S Key

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6668837/nigel-s-key-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201
papers

7,496
citations

44
h-index

84
g-index

219
ext. papers

8,827
ext. citations

5.7
avg, IF

6.18
L-index

#	Paper	IF	Citations
201	Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.. <i>Journal of Oncology Pharmacy Practice</i> , 2022 , 10781552211073883	1.7	2
200	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.. <i>Journal of Thrombosis and Haemostasis</i> , 2022 ,	15.4	2
199	Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study.. <i>British Journal of Haematology</i> , 2022 ,	4.5	
198	Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients. <i>American Journal of Hematology</i> , 2021 ,	7.1	0
197	Rituximab Monotherapy Is Effective for Inhibitor Eradication with Concomitant Porcine Factor VIII Followed By Emicizumab for Bleed Control in Acquired Hemophilia a. <i>Blood</i> , 2021 , 138, 348-348	2.2	1
196	Emicizumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner. <i>Blood</i> , 2021 , 138, 3182-3182	2.2	
195	Pathologically stiff erythrocytes impede contraction of blood clots: Comment. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2893-2894	15.4	1
194	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. <i>Blood Advances</i> , 2021 , 5, 1682-1694	7.8	13
193	Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure. <i>Blood</i> , 2021 , 138, 259-272	2.2	4
192	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. <i>Journal of Trauma and Acute Care Surgery</i> , 2021 , 91, S19-S25	3.3	6
191	Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. <i>Haemophilia</i> , 2021 , 27, e585-e588	3.3	3
190	Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review. <i>Kidney Medicine</i> , 2021 , 3, 607-618	2.8	1
189	Management of inhibitors in persons with non-severe hemophilia A in the United States. <i>American Journal of Hematology</i> , 2021 , 96, E9-E11	7.1	2
188	Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy. <i>Haemophilia</i> , 2021 , 27, e147-e150	3.3	
187	Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After Trauma. <i>Shock</i> , 2021 , 56, 433-439	3.4	2
186	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 172-179	1	2
185	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. <i>Haemophilia</i> , 2021 , 27, 211-220	3.3	2

184	A pilot study of the effect of rivaroxaban in sickle cell anemia. <i>Transfusion</i> , 2021 , 61, 1694-1698	2.9	
183	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. <i>Haemophilia</i> , 2021 , 27, 974-983	3.3	0
182	Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma. <i>Thrombosis Research</i> , 2021 , 204, 22-28	8.2	1
181	Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals. <i>JAMA Network Open</i> , 2021 , 4, e2030435	10.4	3
180	Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. <i>Blood</i> , 2020 , 135, 1783-1787	2.2	19
179	Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	20
178	High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2329-2340	15.4	3
177	Pregnancy in sickle cell trait: what we do and don't know. <i>British Journal of Haematology</i> , 2020 , 190, 328-335	4.3	3
176	Using heparin molecules to manage COVID-2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 518-523	5.1	47
175	Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study. <i>Blood</i> , 2020 , 136, 47-48	2.2	
174	Venous Thromboembolism Incidence and Impact on Survival in Patients with Brain Metastases. <i>Blood</i> , 2020 , 136, 1-1	2.2	
173	Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial. <i>Blood</i> , 2020 , 136, 1-2	2.2	11
172	Development and application of global assays of hyper- and hypofibrinolysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 46-53	5.1	9
171	Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series. <i>Haemophilia</i> , 2020 , 26, e23-e25	3.3	8
170	Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS). <i>American Journal of Hematology</i> , 2020 , 95, 258-266	7.1	7
169	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020 , 25, 1075-1083	5.7	5
168	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020 , 196, 437-443	8.2	
167	Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 2033-2044	9.4	78

166	Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2732-2743	15.4	10
165	An exploratory study of the effects of strenuous exercise on markers of coagulation activation, circulating microparticles, and inflammation in sickle cell trait. <i>EJHaem</i> , 2020 , 1, 251-254	0.9	
164	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S31-S36	8.2	3
163	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. <i>Blood Advances</i> , 2020 , 4, 4739-4747	7.8	1
162	Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. <i>Blood Advances</i> , 2020 , 4, 3688-3698	7.8	11
161	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 789-798	5.1	1
160	Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1725-1732	7	8
159	Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. <i>Blood Advances</i> , 2020 , 4, 6240-6249	7.8	4
158	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. <i>Haematologica</i> , 2020 , 105, 218-225	6.6	57
157	Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 201-216	15.4	1
156	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. <i>Blood</i> , 2020 , 135, 755-765	2.2	26
155	How to discuss gene therapy for haemophilia? A patient and physician perspective. <i>Haemophilia</i> , 2019 , 25, 545-557	3.3	29
154	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. <i>Lancet Haematology</i> , 2019 , 6, e295-e305	14.6	144
153	Neutrophils: back in the thrombosis spotlight. <i>Blood</i> , 2019 , 133, 2186-2197	2.2	66
152	Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. <i>Haematologica</i> , 2019 , 104, 653-658	6.6	24
151	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. <i>Blood</i> , 2019 , 133, 2529-2541	2.2	23
150	Association of sickle cell trait with measures of cognitive function and dementia in African Americans. <i>ENeurologicalSci</i> , 2019 , 16, 100201	2.1	2
149	Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study. <i>American Journal of Hematology</i> , 2019 , 94, 1306-1313	7.1	7

148	Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. <i>Case Reports in Hematology</i> , 2019 , 2019, 2587597	0.7	0
147	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. <i>British Journal of Cancer</i> , 2019 , 121, 359-371	8.7	36
146	All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia [Patients in the United States. <i>Blood</i> , 2019 , 134, 902-902	2.2	2
145	Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer. <i>Blood</i> , 2019 , 134, 634-634	2.2	
144	High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice. <i>Blood</i> , 2019 , 134, 3621-3621	2.2	
143	Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. <i>Blood Advances</i> , 2019 , 3, 1429-1440	7.8	13
142	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. <i>Blood Advances</i> , 2019 , 3, 3241-3247	7.8	37
141	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. <i>HemaSphere</i> , 2019 , 3, e286	0.3	23
140	Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26993	3	6
139	Harold Ross Roberts, MD, 1930-2017. <i>Haemophilia</i> , 2018 , 24, 13-14	3.3	
138	Microparticles in sickle cell disease. <i>Clinical Hemorheology and Microcirculation</i> , 2018 , 68, 319-329	2.5	13
137	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 251-265	7	31
136	Effect of eptifibatid on inflammation during acute pain episodes in sickle cell disease. <i>American Journal of Hematology</i> , 2018 , 93, E99-E101	7.1	3
135	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 407-428	5.1	3
134	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018 , 163, 128-131	8.2	4
133	DDAVP trial in discrepant non-severe haemophilia A patients. <i>Haemophilia</i> , 2018 , 24, e152-e154	3.3	1
132	Red Blood Cell Adhesion to Heme-Activated Endothelial Cells Reflects Clinical Phenotype in Sickle Cell Disease. <i>American Journal of Hematology</i> , 2018 , 93, 1050	7.1	24
131	Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2018 , 132, 2513-2513	2.2	1

130	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. <i>Blood</i> , 2018 , 132, 2514-2514	2.2	1
129	Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy. <i>Blood</i> , 2018 , 132, 1202-1202	2.2	1
128	A cross-sectional analysis of cardiovascular disease in the hemophilia population. <i>Blood Advances</i> , 2018 , 2, 1325-1333	7.8	22
127	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. <i>Blood Advances</i> , 2018 , 2, 3035-3044	7.8	17
126	Elevated hematocrit enhances platelet accumulation following vascular injury. <i>Blood</i> , 2017 , 129, 2537-2546	5.6	59
125	Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2573-2581	1.9	23
124	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , 2017 , 39, 441-447	2.5	42
123	In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. <i>Blood</i> , 2017 , 129, 1021-1029	2.2	123
122	Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function. <i>Blood</i> , 2017 , 129, 799-801	2.2	8
121	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , 2017 , 39, e142-e143	2.5	7
120	Perioperative management of rare coagulation factor deficiency states in cardiac surgery. <i>British Journal of Anaesthesia</i> , 2017 , 119, 354-368	5.4	11
119	Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	60
118	Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. <i>Haemophilia</i> , 2017 , 23, 33-41	3.3	14
117	Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 187-193	15.4	73
116	Adhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes. <i>Blood</i> , 2017 , 130, 959-959	2.2	2
115	Care models in the management of haemophilia: a systematic review. <i>Haemophilia</i> , 2016 , 22 Suppl 3, 31-40	3.3	14
114	Acquired Inhibitors of Coagulation 2016 , 124-133		
113	Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. <i>Blood</i> , 2016 , 127, 1371-3	2.2	15

112	Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1941-1952	15.4	38
111	Von Willebrand Disease 2016 , 94-112		
110	Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy. <i>Haemophilia</i> , 2016 , 22, e549-e551	3.3	8
109	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , 2016 , 76, 3671-5	10.1	23
108	Microparticle analysis in disorders of hemostasis and thrombosis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016 , 89, 111-22	4.6	79
107	Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. <i>Blood Reviews</i> , 2016 , 30, 245-56	11.1	77
106	Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays. <i>Thrombosis Research</i> , 2016 , 139, 90-7	8.2	54
105	Establishing sickle cell diagnostics and characterizing a paediatric sickle cell disease cohort in Malawi. <i>British Journal of Haematology</i> , 2016 , 174, 325-9	4.5	11
104	Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 153-66	15.4	93
103	In vitro and in vivo characterization of a reversible synthetic heparin analog. <i>Thrombosis Research</i> , 2016 , 138, 121-129	8.2	5
102	Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of stroke. <i>JCI Insight</i> , 2016 , 1,	9.9	4
101	Treatment of Venous Thromboembolism in Patients with Hematological Malignancies and Severe Thrombocytopenia: A Retrospective Cohort Analysis. <i>Blood</i> , 2016 , 128, 531-531	2.2	2
100	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. <i>Blood</i> , 2016 , 128, 2478-2478	2.2	2
99	Early Renal Disease in Children with Sickle Cell Disease from Malawi. <i>Blood</i> , 2016 , 128, 1316-1316	2.2	
98	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 42-9	7	19
97	Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1031-42	15.4	32
96	Microparticles in sickle cell anaemia: promise and pitfalls. <i>British Journal of Haematology</i> , 2016 , 174, 16-25	4.0	40
95	Basic Principles Underlying Coagulation 2016 , 1-11		

94 Quantitative Platelet Disorders **2016**, 134-159

93 Qualitative Platelet Disorders **2016**, 160-171

92 Thrombotic Microangiopathies **2016**, 183-194

91 Myeloproliferative Neoplasms: Thrombosis and Hemorrhage **2016**, 210-228

90 Arterial Thrombosis **2016**, 229-239

89 Anticoagulation: Heparins and Vitamin K Antagonists **2016**, 240-252

88 The Direct Oral Anticoagulants **2016**, 253-268

87 Laboratory Tests of Hemostasis **2016**, 12-26

86 Cardiovascular Medicine **2016**, 282-298

85 Cardiothoracic Surgery **2016**, 299-313

1

84 Hepatology **2016**, 329-339

83 Obstetrics, Contraception, and Estrogen Replacement **2016**, 379-392

82 Intensive and Critical Care **2016**, 414-432

81 Transfusion **2016**, 433-443

80 Molecular Diagnostic Approaches to Hemostasis **2016**, 27-41

1

79 Tests of Platelet Function **2016**, 42-62

78 Evaluation of the Bleeding Patient **2016**, 63-78

77 Hemophilia A and B **2016**, 79-93

1

76 The Rarer Inherited Coagulation Disorders **2016**, 113-123

75 OC-04 - Tissue factor positive microvesicles activate platelets in vitro and in vivo and enhance thrombosis in mice. *Thrombosis Research*, **2016**, 140 Suppl 1, S169-70 8.2 1

74 How I treat patients with inherited bleeding disorders who need anticoagulant therapy. *Blood*, **2016**, 128, 178-84 2.2 51

73 Genetic basis of ethnic disparities in VTE risk. *Blood*, **2016**, 127, 1844-5 2.2 4

72 NHF-McMaster Guideline on Care Models for Haemophilia Management. *Haemophilia*, **2016**, 22 Suppl 3, 6-16 3.3 40

71 Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. *Clinical Science*, **2016**, 130, 433-40 6.5 18

70 Corrigendum to "Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays" [Thromb. Res. 139 (2016) 90-97]. *Thrombosis Research*, **2016**, 147, 63 8.2

69 Protocol adherence when managing massive bleeding following complex cardiac surgery: a study design pilot. *Journal of Cardiothoracic and Vascular Anesthesia*, **2015**, 29, 303-10 2.1 9

68 Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. *Blood*, **2015**, 125, 3647-50 2.2 32

67 Impact of an innovative blood factor stewardship program on drug expense and patient care. *American Journal of Health-System Pharmacy*, **2015**, 72, 1579-84 2.2 17

66 Prospective study of sickle cell trait and venous thromboembolism incidence. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 2-9 15.4 72

65 Management of adult non-severe haemophilia A patients with inhibitors: a practice-pattern survey. *Haemophilia*, **2015**, 21, e422-4 3.3 2

64 Sickle Cell Trait Worsens Oxidative Stress, Abnormal Blood Rheology, and Vascular Dysfunction in Type 2 Diabetes. *Diabetes Care*, **2015**, 38, 2120-7 14.6 21

63 New players in Trousseau syndrome. *Blood*, **2015**, 126, 1270-2 2.2

62 Coagulation activation in sickle cell trait: an exploratory study. *British Journal of Haematology*, **2015**, 171, 638-46 4.5 19

61 Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. *British Journal of Haematology*, **2015**, 170, 5-14 4.5 36

60 Cluster of inhibitors among adult inpatients with haemophilia in a single institution. *Haemophilia*, **2015**, 21, e325-8 3.3

59 Excess of heme induces tissue factor-dependent activation of coagulation in mice. *Haematologica*, **2015**, 100, 308-14 6.6 58

58	Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. <i>Thrombosis Research</i> , 2015 , 135 Suppl 1, S46-8	8.2	11
57	Type-2 Phosphatidylserine (PS)-Positive Erythrocytes and Their Association with Markers of Hemolysis and Hemostatic Activation in Children with Sickle Cell Disease (SCD). <i>Blood</i> , 2015 , 126, 943-943 ^{2,2}		1
56	HemoglobinA2 Levels Associate with Lower ESA-Dose in African-Americans with Sickle Cell Trait and End-Stage Kidney Disease. <i>Blood</i> , 2015 , 126, 3407-3407	2.2	
55	Purified DNA, but Not Neutrophil Extracellular Traps (NETs), Promotes Contact Activation of Coagulation. <i>Blood</i> , 2015 , 126, 767-767	2.2	
54	Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. <i>Nature Chemical Biology</i> , 2014 , 10, 248-50	11.7	147
53	Definitions in hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1935-9	15.4	354
52	Red blood cells and thrombin generation in sickle cell disease. <i>Thrombosis Research</i> , 2014 , 133 Suppl 1, S52-3	8.2	8
51	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. <i>Blood</i> , 2014 , 123, 1747-56	2.2	84
50	Epidemiologic and clinical data linking factors XI and XII to thrombosis. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 66-70	3.1	58
49	Joint WFH-ISTH session: issues in clinical trial design. <i>Haemophilia</i> , 2014 , 20 Suppl 4, 137-44	3.3	6
48	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2115-25	27.4	126
47	Impact of sickle hemoglobinopathies on pregnancy-related venous thromboembolism. <i>American Journal of Perinatology</i> , 2014 , 31, 805-9	3.3	18
46	Sickle cell trait and incident ischemic stroke in the Atherosclerosis Risk in Communities study. <i>Stroke</i> , 2014 , 45, 2863-7	6.7	46
45	Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. <i>Thrombosis Research</i> , 2014 , 133, 187-9	8.2	23
44	Guidelines for the management of hemophilia. <i>Haemophilia</i> , 2013 , 19, e1-47	3.3	1227
43	Bench to bedside: new developments in our understanding of the pathophysiology of thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 342-5	5.1	5
42	Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. <i>Haemophilia</i> , 2012 , 18, 798-804	3.3	48
41	Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. <i>Blood</i> , 2012 , 120, 636-46	2.2	76

40	Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. <i>Blood</i> , 2012 , 119, 5543-52	2.2	148
39	Association of coagulation activation with clinical complications in sickle cell disease. <i>PLoS ONE</i> , 2012 , 7, e29786	3.7	78
38	Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. <i>Kidney International</i> , 2011 , 80, 992-999	9.9	8
37	Vascular haemostasis. <i>Haemophilia</i> , 2010 , 16 Suppl 5, 146-51	3.3	1
36	High prevalence of sickle cell trait in African Americans with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 413-7	12.7	61
35	Sickle-cell trait: novel clinical significance. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 418-22	3.1	72
34	Tissue factor and its measurement in whole blood, plasma, and microparticles. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 865-75	5.3	81
33	Analysis of tissue factor positive microparticles. <i>Thrombosis Research</i> , 2010 , 125 Suppl 1, S42-5	8.2	50
32	Current treatment of venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 372-5	9.4	17
31	Membrane microparticles in VTE and cancer. <i>Thrombosis Research</i> , 2010 , 125 Suppl 2, S80-3	8.2	25
30	Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 200, 620.e1-3	6.4	44
29	Platelet tissue factor: how did it get there and is it important?. <i>Seminars in Hematology</i> , 2008 , 45, S16-204		10
28	Hypercoagulability in sickle cell disease: new approaches to an old problem. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 91-6	3.1	134
27	Sickle cell trait and the risk of venous thromboembolism among blacks. <i>Blood</i> , 2007 , 110, 908-12	2.2	177
26	Coagulation factor concentrates: past, present, and future. <i>Lancet, The</i> , 2007 , 370, 439-48	4.0	152
25	Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 1687-93	9.4	458
24	Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2007 , 71, 38-45	4.6	109
23	Tissue factor; from Morawitz to microparticles. <i>Transactions of the American Clinical and Climatological Association</i> , 2007 , 118, 165-73	0.9	12

22	Proteomics in the Study of Qualitative Platelet Defects: Validation of the Approach in the Gray Platelet Syndrome and Quebec Platelet Disorder.. <i>Blood</i> , 2007 , 110, 3900-3900	2.2	
21	Sickle Cell Trait, Oral Contraceptives, and the Risk of Venous Thromboembolism.. <i>Blood</i> , 2007 , 110, 1627-1627	1	1
20	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. <i>Blood</i> , 2007 , 110, 3951-3951	2	1
19	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. <i>Blood</i> , 2007 , 110, 2160.5-2160.5	2	1
18	Current insights on the risk of thrombogenicity with off-label use of rFVIIa. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 34-5	0.6	4
17	Diagnostic approaches to bleeding disorders. <i>Hematology</i> , 2005 , 10 Suppl 1, 29-32	2.2	1
16	Administration of FFP Repletes and Sustains the Megakaryocyte/Platelet-Derived Factor V Pool To Confer Hemostatic Competence in a Factor V-Deficient Individual.. <i>Blood</i> , 2005 , 106, 1779-1779	2.2	2
15	Inhibitors in congenital coagulation disorders. <i>British Journal of Haematology</i> , 2004 , 127, 379-91	4.5	106
14	Measuring circulating cell-derived microparticles. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1848-1850	18.1	22
13	Views on methods for monitoring recombinant factor VIIa in inhibitor patients. <i>Seminars in Hematology</i> , 2004 , 41, 51-4	4	25
12	Phosphatidylserine-Positive Erythrocytes Modulate Tissue Factor Activity In Vivo and In Vitro in Sickle Cell Disease.. <i>Blood</i> , 2004 , 104, 240-240	2.2	
11	Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. <i>Blood</i> , 2003 , 102, 2678-83	2.2	435
10	Coagulation inhibition for sepsis. <i>Current Opinion in Hematology</i> , 2002 , 9, 416-21	3.3	7
9	Hyperhomocyst(e)inemia and Thrombophilia. <i>Archives of Pathology and Laboratory Medicine</i> , 2002 , 126, 1367-75	5	55
8	Tissue factor as a therapeutic target. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 375-6	7	3
7	Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. <i>Thrombosis and Haemostasis</i> , 1998 , 80, 912-918	7	325
6	Whole Blood Tissue Factor Procoagulant Activity Is Elevated in Patients With Sickle Cell Disease. <i>Blood</i> , 1998 , 91, 4216-4223	2.2	220
5	Whole Blood Tissue Factor Procoagulant Activity Is Elevated in Patients With Sickle Cell Disease. <i>Blood</i> , 1998 , 91, 4216-4223	2.2	5

4	Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. <i>Blood</i> , 1998 , 91, 4216-23	2.2	64
3	Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. <i>Thrombosis and Haemostasis</i> , 1998 , 80, 912-8	7	70
2	Hemolytic anemia in protoporphyria: possible precipitating role of liver failure and photic stress. <i>American Journal of Hematology</i> , 1992 , 39, 202-7	7.1	25
1	Reference Ranges444-451		